Halozyme Therapeutics, Inc. (NASDAQ:HALO) Short Interest Update

Halozyme Therapeutics, Inc. (NASDAQ:HALO) was the recipient of a large increase in short interest in the month of January. As of January 15th, there was short interest totalling 9,500,000 shares, an increase of 8.1% from the December 31st total of 8,790,000 shares. Based on an average daily volume of 1,670,000 shares, the short-interest ratio is presently 5.7 days. Approximately 7.6% of the shares of the stock are short sold.

Halozyme Therapeutics Price Performance

Shares of Halozyme Therapeutics stock opened at $56.28 on Tuesday. The stock has a market capitalization of $7.16 billion, a P/E ratio of 18.64, a price-to-earnings-growth ratio of 0.43 and a beta of 1.25. Halozyme Therapeutics has a one year low of $33.15 and a one year high of $65.53. The company has a debt-to-equity ratio of 3.32, a current ratio of 10.36 and a quick ratio of 9.15. The business’s 50 day simple moving average is $50.82 and its two-hundred day simple moving average is $54.33.

Analyst Ratings Changes

A number of research firms have commented on HALO. Wells Fargo & Company cut their price target on shares of Halozyme Therapeutics from $62.00 to $57.00 and set an “equal weight” rating for the company in a research note on Monday, January 13th. Cowen reissued a “buy” rating on shares of Halozyme Therapeutics in a research note on Friday, October 18th. HC Wainwright reaffirmed a “buy” rating and set a $70.00 price target on shares of Halozyme Therapeutics in a research note on Tuesday. Piper Sandler increased their price objective on Halozyme Therapeutics from $52.00 to $53.00 and gave the company a “neutral” rating in a research report on Friday, January 10th. Finally, JMP Securities boosted their target price on Halozyme Therapeutics from $72.00 to $73.00 and gave the stock a “market outperform” rating in a research report on Friday, November 1st. Four analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. Based on data from MarketBeat, Halozyme Therapeutics presently has a consensus rating of “Moderate Buy” and an average target price of $60.89.

Insider Buying and Selling at Halozyme Therapeutics

In other news, Director Jeffrey William Henderson sold 10,000 shares of the business’s stock in a transaction dated Monday, January 6th. The stock was sold at an average price of $50.01, for a total transaction of $500,100.00. Following the completion of the transaction, the director now owns 43,611 shares of the company’s stock, valued at approximately $2,180,986.11. The trade was a 18.65 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 2.70% of the company’s stock.

Institutional Investors Weigh In On Halozyme Therapeutics

Several institutional investors have recently added to or reduced their stakes in the company. Hussman Strategic Advisors Inc. raised its stake in shares of Halozyme Therapeutics by 75.0% during the fourth quarter. Hussman Strategic Advisors Inc. now owns 73,500 shares of the biopharmaceutical company’s stock valued at $3,514,000 after acquiring an additional 31,500 shares during the last quarter. Private Advisor Group LLC increased its holdings in Halozyme Therapeutics by 23.8% during the 4th quarter. Private Advisor Group LLC now owns 29,908 shares of the biopharmaceutical company’s stock valued at $1,430,000 after purchasing an additional 5,745 shares during the period. Convergence Investment Partners LLC raised its position in Halozyme Therapeutics by 25.9% during the 4th quarter. Convergence Investment Partners LLC now owns 34,713 shares of the biopharmaceutical company’s stock valued at $1,660,000 after purchasing an additional 7,151 shares during the last quarter. Venturi Wealth Management LLC purchased a new stake in Halozyme Therapeutics in the 4th quarter worth approximately $69,000. Finally, State of New Jersey Common Pension Fund D grew its position in shares of Halozyme Therapeutics by 0.6% in the 4th quarter. State of New Jersey Common Pension Fund D now owns 47,663 shares of the biopharmaceutical company’s stock worth $2,279,000 after buying an additional 302 shares during the last quarter. Hedge funds and other institutional investors own 97.79% of the company’s stock.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.